NCT06121960

Brief Summary

The goal of this Prospective, monocentric, non-randomized, open-label study aimed at evaluating the variation of FEV1 during a state of self-induced cognitive trance participant population: Person with expertise in the practice of TCAI can be inclued. (at least 6 months, in order to be able to control the depth of the trance and to have a motor control allowing the realization of a spirometry) The main question: Study the significant variation of FEV1 before, during, or after the state of self-induced cognitive trance

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
9

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started May 2023

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 26, 2023

Completed
Same day until next milestone

Study Start

First participant enrolled

May 26, 2023

Completed
6 months until next milestone

First Posted

Study publicly available on registry

November 8, 2023

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2024

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 7, 2024

Completed
Last Updated

March 8, 2024

Status Verified

March 1, 2024

Enrollment Period

7 months

First QC Date

May 26, 2023

Last Update Submit

March 7, 2024

Conditions

Keywords

spirometryTCAI (Cognitive-induced trance)

Outcome Measures

Primary Outcomes (1)

  • FEV during a state of self-induced cognitive trance

    variation of forced exhaled volume in one second between pre and post phase of cognitive transe

    3 month

Secondary Outcomes (6)

  • PEF during a state of self-induced cognitive trance

    3 month

  • DEM25/50/75 during a state of self-induced cognitive trance

    3 month

  • inspiratory capacity during a state of self-induced cognitive trance

    3 month

  • respiratory rate during a state of self-induced cognitive trance

    3 month

  • SpO2 during a state of self-induced cognitive trance

    3 month

  • +1 more secondary outcomes

Study Arms (1)

Interventionnal

EXPERIMENTAL

Measure DEP, DEM25, DEM 50, DEM 75, FVC, Inspiratory capacity, SpO2, Respiratory rate before, during, or after the state of self-induced cognitive trance Evolution of the feeling of self-efficacy, assessed by questionnaire.

Diagnostic Test: spirometry

Interventions

spirometryDIAGNOSTIC_TEST

Inclusion visit: Performing spirometry. Visit 2 (in the month following the inclusion visit): Induction of a self-induced cognitive trance by the participant; performance of spirometry before, during the trance then 8 minutes after the end of the trance Actimetry during trance

Interventionnal

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Person over 18 years old
  • Person with expertise in the practice of TCAI. (at least 6 months, in order to be able to control the depth of the trance and to have a motor control allowing the realization of a spirometry)
  • Person affiliated with social security or beneficiary of such a scheme.
  • Person having given, in writing, their free and informed consent to participate in the study

You may not qualify if:

  • Person deprived of liberty by judicial or administrative decision, person subject to a measure of legal protection.
  • Person likely, according to the investigator's assessment, not to be cooperative or respectful of the obligations inherent in participation in the study
  • Person with a psychiatric, neurological or cardiovascular disease.
  • Person with a chronic respiratory disease, for example: asthma, COPD, interstitial lung disease, bronchial dilation, cystic fibrosis,
  • Person with a history of exercise-induced bronchospasm.
  • Person taking inhaled treatments (corticotherapy, bronchodilators, anticholinergics)
  • Pregnant woman (declarative).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Centre Hospitalier Metropole Savoie

Chambéry, Savoie, 73011, France

Location

MeSH Terms

Conditions

Respiratory Aspiration

Interventions

Spirometry

Condition Hierarchy (Ancestors)

Respiration DisordersRespiratory Tract DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Respiratory Function TestsDiagnostic Techniques, Respiratory SystemDiagnostic Techniques and ProceduresDiagnosis

Study Officials

  • Pierre IDEE

    CH Metropole Savoie

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Masking Details
Person with expertise in the practice of TCAI. (at least 6 months, in order to be able to control the depth of the trance and to have a motor control allowing the realization of a spirometry)
Purpose
BASIC SCIENCE
Intervention Model
SINGLE GROUP
Model Details: Prospective, monocentric, non-randomized, open-label study.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 26, 2023

First Posted

November 8, 2023

Study Start

May 26, 2023

Primary Completion

January 1, 2024

Study Completion

March 7, 2024

Last Updated

March 8, 2024

Record last verified: 2024-03

Data Sharing

IPD Sharing
Will not share

Locations